Clinical trials referenced in this document:
Documents that mention this clinical trial
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
https://doi.org/10.1186/s12967-020-02424-7
Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING
https://doi.org/10.1136/jitc-2022-006235
Funding for this research was provided by:
Kreftforeningen (182632-2016)
Helse Sør-Øst RHF (2017100, 2017122)
Roche
Article History
Received: 27 April 2020
Accepted: 17 June 2020
First Online: 23 June 2020
Ethics approval and consent to participate
: The ALICE trial has been approved by the Norwegian and Danish Medical Agencies and Ethics Committees. The study is performed in compliance with the World Medical Association Declaration of Helsinki and ICH E6 for Good Clinical Practice. Signed informed consent is obtained from all patients.
: All authors have consented to the publication. Approval has also been obtained from Roche.
: The authors declare that they have no competing interests.